The CRL3<sup>gigaxonin</sup> ubiquitin ligase-USP15 pathway governs the destruction of neurofilament proteins.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 37903270.
- Also identified by DOI 10.1073/pnas.2306395120 and PMC identifier 10636361.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Giant axonal neuropathy (GAN) is caused by mutations in the <i>GAN</i> gene encoding for gigaxonin (GIG), which functions as an adaptor of the CUL3-RBX1-GIG (CRL3<sup>GIG</sup>) E3 ubiquitin ligase complex. The pathological hallmark of GAN is characterized by the accumulation of densely packed neurofilaments (NFs) in the axons. However, there are fundamental knowledge gaps in our understanding of the molecular mechanisms by which the ubiquitin-proteasome system controls the homeostasis of NF proteins. Recently, the deubiquitylating enzyme USP15 was reported to play a crucial role in regulating ubiquitylation and proteasomal degradation of CRL4<sup>CRBN</sup> substrate proteins. Here, we report that the CRL3<sup>GIG</sup>-USP15 pathway governs the destruction of NF proteins NEFL and INA. We identified a specific degron called NEFL<sup>L12</sup> degron for CRL3<sup>GIG</sup>. Notably, mutations in the C-terminal Kelch domain of GIG, represented by L309R, R545C, and C570Y, disrupted the binding of GIG to NEFL and INA, leading to the accumulation of these NF proteins. This accounts for the loss-of-function mutations in GAN patients. In addition to regulating NFs, CRL3<sup>GIG</sup> also controls actin filaments by directly targeting actin-filament-binding regulatory proteins TPM1, TPM2, TAGLN, and CNN2 for proteasomal degradation. Thus, our findings broadly impact the field by providing fundamental mechanistic insights into regulating extremely long-lived NF proteins NEFL and INA by the CRL3<sup>GIG</sup>-USP15 pathway and offering previously unexplored therapeutic opportunities to treat GAN patients and other neurodegenerative diseases by explicitly targeting downstream substrates of CRL3<sup>GIG</sup>.
Medical subject headings
- Neurofilament Proteins
- Giant Axonal Neuropathy